Death from COVID-19 of a 57-year-old man refusing medical care and self-medicating with ivermectin
Jazyk angličtina Země Česko Médium print
Typ dokumentu kazuistiky, časopisecké články
PubMed
36718931
DOI
10.21101/cejph.a7643
Knihovny.cz E-zdroje
- Klíčová slova
- COVID-19, ivermectin, misinformation, refusing medical care,
- MeSH
- COVID-19 * MeSH
- ivermektin terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- SARS-CoV-2 MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- ivermektin MeSH
Since December 2019, the new SARS-CoV-2 coronavirus causes COVID-19 disease worldwide, which occurs mainly in unvaccinated elderly and polymorbid patients with a more severe course and increased risk of complications and death. Vaccination and specific therapy for the disease using mainly new antiviral drugs are the way to reduce the number of infected, hospitalized patients with a more severe course. We present a case report of an at-risk polymorbid 57-year-old man who refused vaccination and standard treatment for COVID-19 disease based on misinformation from the community. He self-treated himself with high dose of ivermectin. The patient died at home 14 days after the onset of symptoms.
Zobrazit více v PubMed
Wassie GT, Azene AG, Bantie GM, Dessie G, Aragaw AM. Incubation period of severe acute respiratory syndrome novel coronavirus 2 that causes coronavirus disease 2019: a systematic review and meta-analysis. Cur Ther Res Clin Exp. 2020;93:100607. doi: 10.1016/j.curtheres.2020.100607. PubMed DOI
Akoumianaki E, Vaporidi K, Bolaki M, Georgopoulos D. Happy or silent hypoxia in COVID-19 - a misnomer born in the pandemic era. Front Physiol. 2021 Oct 18;12:745634. doi: 10.3389/fphys.2021.745634. PubMed DOI
Hill A, Mirchandani M, Pilkington V. Ivermectin for COVID-19: addressing potential bias and medical fraud. Open Forum Infect Dis. 2022 Feb;9(2):ofab645. doi: 10.1093/ofid/ofab645. PubMed DOI
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020 Nov 5;383(19):1827-37. PubMed DOI
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020 Sep 15;324(11):1048-57. PubMed DOI
RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. PubMed DOI
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270-9. PubMed DOI
Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37. doi: 10.1186/s40364-020-00217-0. PubMed DOI
Džupová O, Moravec M, Bartoš H, Brestovanský P, Tencer T, Hyánek T, et al. COVID-19 severe pneumonia: prospective multicentre study on demands on intensive care capacities. Cent Eur J Public Health. 2021 Mar;29(1):3-8. PubMed DOI
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-8. PubMed DOI
